Watch ENSC. Know when insiders buy.
One email the day a filing lands. Free.
ENSC
Ensysce Biosciences, Inc.
0.45
−0.02 −4.46%
USD · close Oct 26
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.8MP/E —DIV YIELD —FCF YIELD —REV TTM $4.5M −39.3%NET INCOME −$12.6MNET CASH —52W 0.25 – 2.18SEC XBRL · TTM TO Invalid Date
How ENSC rewrote its risk factors
Text kept
98%
of sentences unchanged
Added
9
new sentences
Dropped
6
sentences removed
Length
+85
words, now 22,401
New in FY2025
- If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate our product discovery and development programs or commercialization efforts.
- Please see the risk factors under “ Risks Related to the Ownership of Common Stock and Financial Reporting .” We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2026, while advancing our main product candidates such as, PF614 and PF614-MPAR and nafamostat through their respective next phases of clinical development.
- We currently have eight full-time employees and two part-time employees.
- Certain warrants we have issued contain such restrictions including a pledge of substantially all of our tangible and intangible assets, including our intellectual property.
- If we are unable to regain and maintain compliance with the listing standards of Nasdaq, our common stock could be delisted and may become subject to “penny stock” rules, which could have a material adverse effect on the liquidity of our common stock, the ability of investors to sell their shares and our ability to raise funding.
- As of September 30, 2025, we were not in compliance with that stockholders’ equity requirement but on November 14, 2025, we raised additional capital and our stockholders’ equity then exceeded the requirement.
- On February 25, 2026, we received notice from Nasdaq that we are no longer in compliance with the bid price requirement because the price of our common stock has remained below $1.00 for more than 30 consecutive business days.
- We have until August 24, 2026, and possibly longer, to regain compliance with the bid price requirement.
- There can be no assurance that we will be able to regain and/or maintain compliance with such Nasdaq Listing Rules and our common stock could be delisted.
Gone since FY2024
- If we are unable raise capital when needed, we could be forced to delay, reduce or terminate our product discovery and development programs or commercialization efforts.
- Please see the risk factors under “ Risks Related to the Ownership of Common Stock and Financial Reporting .” We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2025, while advancing our main product candidates such as, PF614 and PF614-MPAR and nafamostat through their respective next phases of clinical development.
- We currently only have seven full-time employees, one part-time employee and one consultant and we expect to add additional employees.
- The Investor Notes contain such restrictions including a pledge of substantially all of our tangible and intangible assets, including our intellectual property.
- If we are unable to maintain compliance with the listing standards of Nasdaq, our common stock could be delisted and may become subject to “penny stock” rules, which could have a material adverse effect on the liquidity of our common stock, the ability of investors to sell their shares and our ability to raise funding.
- There can be no assurance that we will be able to maintain compliance with such Nasdaq Listing Rules and our common stock could be delisted.
Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.